TWA
CRBP icon

TCI Wealth Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

TCI Wealth Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3
Closed – – 1558
2020
Q3 		$0 Hold
3
– – ﹤0.01% 1549
2020
Q2 		$1K Hold
3
– – ﹤0.01% 1227
2020
Q1 		$1K Hold
3
– – ﹤0.01% 1215
2019
Q4 		$1K Hold
3
– – ﹤0.01% 1310
2019
Q3 		$0 Sell
3
-3
-50% -$523 ﹤0.01% 1510
2019
Q2 		$1K Buy
6
+3
+100% +$642 ﹤0.01% 1169
2019
Q1 		$1K Hold
3
– – ﹤0.01% 1183
2018
Q4 		$1K Hold
3
– – ﹤0.01% 1180
2018
Q3 		$1K Sell
3
-14
-82% -$2.26K ﹤0.01% 1187
2018
Q2 		$3K Sell
17
-3
-15% -$545 ﹤0.01% 925
2018
Q1 		$4K Buy
20
+3
+18% +$674 ﹤0.01% 772
2017
Q4 		$4K Hold
17
– – ﹤0.01% 820
2017
Q3 		$4K Sell
17
-3
-15% -$587 ﹤0.01% 766
2017
Q2 		$4K Buy
+20
New +$3.92K ﹤0.01% 793

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCI Wealth Advisors's CRBP Position: Q4 2020 in Review

TCI Wealth Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q4 2020, closing a stake of 3 shares.

TCI Wealth Advisors first reported a position in CRBP in Q2 2017 and held it in 14 quarters. The position peaked at $4K in Q1 2018. 107 funds tracked by Wall St. Rank hold CRBP as of Q4 2020.

  • TCI Wealth Advisors reported no remaining Corbus Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • TCI Wealth Advisors sold 3 Corbus Pharmaceuticals shares in Q4 2020.
  • TCI Wealth Advisors first reported a position in Corbus Pharmaceuticals in Q2 2017 and held it in 14 quarters.
  • TCI Wealth Advisors's Corbus Pharmaceuticals position peaked at $4K in Q1 2018.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2020.

Based on TCI Wealth Advisors's 13F filing for Q4 2020, filed 21 Jan 2021.